ISTH 2022 Congress
Acquired Bleeding Disorders » Novel Therapies in the Management of Acquired Bleeding
Theme Navigation
- ISTH 2022 Congress
- Acquired Bleeding Disorders
- Novel Therapies in the Management of Acquired Bleeding
- Acquired Bleeding Disorders
-
Abstract Number: PO0048
A Cardiac Amyloidosis Presentation: Atrial Mass Versus Thrombus
-
Abstract Number: PB1001
A Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Hemostatic and Anti-Inflammatory Activities
-
Abstract Number: PB1003
CT-001 is a Rapid Clearing Factor VIIa with Enhanced Hemostatic Activity and Safety in Mouse Models of Acute Bleeding
-
Abstract Number: PB1002
Daratumumab as an Adjunctive Therapy for Acquired Hemophilia A with Poor Prognostic Markers
-
Abstract Number: VPB1006
Mini-invasive surgical treatment of haemorrhoiadal bleeding in patients with cardiovascular disease under antithrombotic therapy
-
Abstract Number: PB0008
Neutralizing anti-emicizumab antibodies in a patient with Acquired Hemophilia A
-
Abstract Number: VPB1007
Overview of Hemostatic Effects of Exogenous Fibrin Monomer with Systemic Use in the Experiment
-
Abstract Number: PB0007
Post-partum Acquired Haemophilia A in the COVID era – building the case for Emicizumab?
-
Abstract Number: PB1005
Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors
-
Abstract Number: OC 61.4
Supercharged platelets as a novel therapy for reducing blood loss post-cardiac surgery
-
Abstract Number: PB1000
The Loss of High Molecular Weight Von Willebrand Factor Multimers under Shear Conditions in Sheep is Not Solely ADAMTS13 Dependent
-
Abstract Number: PB0999
Update in The Management Tools of Thrombotic Thrombocytopenic Purpura(TTP) As One of the Rare Hematological Disorders with A Highlight On the Cost Value of Such Diseases